|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| REVENUES: | |||||
| Collaboration Revenues | |||||
| Royalties, License and Other Revenues | |||||
| Total revenues | |||||
| OPERATING EXPENSES: | |||||
| Cost of sales | |||||
| Gross profit | |||||
| Cost of royalties | |||||
| Research and development | |||||
| General and administrative | |||||
| Loss on impairment of intangible asset (Note 6 and Note 13) | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| OTHER INCOME (EXPENSES): | |||||
| Interest income, net | |||||
| Loss on marketable equity securities, net | |||||
| Change in fair value of warrant liability | |||||
| Foreign currency transaction gain (loss), net | |||||
| Other income (expense), net | |||||
| Total other income (expenses) | |||||
| LOSS BEFORE INCOME TAXES | |||||
| Income tax benefit | |||||
| NET LOSS | |||||
| Net (income) loss attributable to noncontrolling interest | |||||
| NET LOSS ATTRIBUTABLE TO LINEAGE | |||||
| Net loss per common share attributable to Lineage basic | |||||
| Net loss per common share attributable to Lineage diluted | |||||
| Weighted-average common shares used to compute net loss per common share, basic | |||||
| Weighted-average common shares used to compute net loss per common share, diluted | |||||
Loading...